Concepts (337)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hearing Loss | 68 | 2025 | 214 | 14.870 |
Why?
|
| Hearing Aids | 13 | 2025 | 32 | 4.090 |
Why?
|
| Cognitive Dysfunction | 15 | 2025 | 317 | 2.760 |
Why?
|
| Cochlear Implants | 4 | 2017 | 59 | 1.520 |
Why?
|
| Aged | 71 | 2025 | 21502 | 1.390 |
Why?
|
| Geriatrics | 3 | 2021 | 76 | 1.270 |
Why?
|
| Ependymoma | 3 | 2025 | 176 | 1.250 |
Why?
|
| Atherosclerosis | 9 | 2025 | 1002 | 1.200 |
Why?
|
| Aging | 16 | 2025 | 1280 | 0.960 |
Why?
|
| Loneliness | 3 | 2025 | 35 | 0.950 |
Why?
|
| Delivery of Health Care | 4 | 2022 | 683 | 0.930 |
Why?
|
| Exercise | 5 | 2025 | 873 | 0.930 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2024 | 216 | 0.920 |
Why?
|
| Aged, 80 and over | 35 | 2025 | 7142 | 0.890 |
Why?
|
| Brain Neoplasms | 6 | 2023 | 1406 | 0.870 |
Why?
|
| Community Health Workers | 2 | 2022 | 77 | 0.860 |
Why?
|
| Male | 77 | 2025 | 65597 | 0.860 |
Why?
|
| Gangliosides | 1 | 2024 | 73 | 0.830 |
Why?
|
| Mobility Limitation | 2 | 2021 | 33 | 0.830 |
Why?
|
| Cognition | 9 | 2025 | 818 | 0.800 |
Why?
|
| Female | 77 | 2025 | 71508 | 0.790 |
Why?
|
| Activities of Daily Living | 3 | 2022 | 432 | 0.790 |
Why?
|
| Retinoblastoma | 2 | 2021 | 117 | 0.780 |
Why?
|
| Retinal Neoplasms | 2 | 2021 | 103 | 0.780 |
Why?
|
| Quality of Life | 6 | 2024 | 2168 | 0.770 |
Why?
|
| Accidental Falls | 3 | 2025 | 120 | 0.760 |
Why?
|
| Depression | 6 | 2024 | 1366 | 0.760 |
Why?
|
| Humans | 103 | 2025 | 133384 | 0.740 |
Why?
|
| Dementia | 6 | 2022 | 489 | 0.700 |
Why?
|
| Health Services for the Aged | 1 | 2021 | 40 | 0.690 |
Why?
|
| Health Education | 5 | 2025 | 232 | 0.690 |
Why?
|
| Pyrimidines | 2 | 2021 | 420 | 0.680 |
Why?
|
| Geriatric Assessment | 5 | 2024 | 191 | 0.670 |
Why?
|
| Hearing | 7 | 2023 | 62 | 0.610 |
Why?
|
| Deaf-Blind Disorders | 1 | 2018 | 1 | 0.600 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2018 | 3 | 0.600 |
Why?
|
| Pyrazoles | 1 | 2021 | 334 | 0.590 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2020 | 480 | 0.590 |
Why?
|
| Neurosurgical Procedures | 2 | 2024 | 316 | 0.580 |
Why?
|
| Communication | 3 | 2024 | 542 | 0.580 |
Why?
|
| Speech Perception | 3 | 2024 | 57 | 0.540 |
Why?
|
| Congresses as Topic | 1 | 2018 | 191 | 0.540 |
Why?
|
| Independent Living | 5 | 2024 | 72 | 0.530 |
Why?
|
| Mental Health Services | 1 | 2020 | 279 | 0.530 |
Why?
|
| Body Composition | 1 | 2020 | 563 | 0.530 |
Why?
|
| Cross-Sectional Studies | 16 | 2024 | 3741 | 0.510 |
Why?
|
| Audiometry, Pure-Tone | 9 | 2025 | 25 | 0.500 |
Why?
|
| Prospective Studies | 16 | 2025 | 6585 | 0.500 |
Why?
|
| Cost of Illness | 1 | 2017 | 277 | 0.480 |
Why?
|
| Health Care Costs | 1 | 2019 | 409 | 0.470 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 168 | 0.470 |
Why?
|
| Germ-Line Mutation | 4 | 2025 | 368 | 0.460 |
Why?
|
| Accelerometry | 3 | 2025 | 64 | 0.460 |
Why?
|
| Stress, Psychological | 1 | 2020 | 604 | 0.460 |
Why?
|
| Middle Aged | 23 | 2025 | 28987 | 0.450 |
Why?
|
| Computers | 1 | 2014 | 70 | 0.440 |
Why?
|
| Ear Diseases | 1 | 2014 | 21 | 0.440 |
Why?
|
| Vision Disorders | 5 | 2023 | 220 | 0.440 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 401 | 0.440 |
Why?
|
| Societies, Medical | 1 | 2018 | 779 | 0.430 |
Why?
|
| Health Status Indicators | 1 | 2014 | 129 | 0.430 |
Why?
|
| Social Environment | 1 | 2014 | 124 | 0.420 |
Why?
|
| Age Factors | 8 | 2022 | 2956 | 0.410 |
Why?
|
| Ribonuclease III | 2 | 2025 | 103 | 0.400 |
Why?
|
| United States | 20 | 2025 | 11727 | 0.400 |
Why?
|
| Prevalence | 9 | 2023 | 2634 | 0.390 |
Why?
|
| Language | 1 | 2014 | 223 | 0.390 |
Why?
|
| Noise | 2 | 2024 | 21 | 0.380 |
Why?
|
| Glioma | 3 | 2024 | 535 | 0.380 |
Why?
|
| Presbycusis | 3 | 2024 | 4 | 0.360 |
Why?
|
| Child | 20 | 2025 | 25869 | 0.330 |
Why?
|
| Leisure Activities | 3 | 2025 | 10 | 0.330 |
Why?
|
| Risk Factors | 17 | 2025 | 10957 | 0.330 |
Why?
|
| Carotid Artery Diseases | 2 | 2023 | 148 | 0.320 |
Why?
|
| Walking | 3 | 2025 | 233 | 0.300 |
Why?
|
| Social Isolation | 2 | 2025 | 48 | 0.290 |
Why?
|
| Disability Evaluation | 3 | 2020 | 195 | 0.290 |
Why?
|
| Child, Preschool | 12 | 2025 | 14875 | 0.260 |
Why?
|
| Medicare | 4 | 2023 | 468 | 0.240 |
Why?
|
| Baltimore | 3 | 2024 | 17 | 0.240 |
Why?
|
| Neoplasm Grading | 2 | 2024 | 307 | 0.240 |
Why?
|
| Pineal Gland | 1 | 2025 | 22 | 0.230 |
Why?
|
| Pinealoma | 1 | 2025 | 23 | 0.230 |
Why?
|
| Longitudinal Studies | 7 | 2024 | 1513 | 0.230 |
Why?
|
| Odontoid Process | 1 | 2024 | 10 | 0.230 |
Why?
|
| Chordoma | 1 | 2024 | 23 | 0.230 |
Why?
|
| Television | 1 | 2025 | 71 | 0.220 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2025 | 72 | 0.220 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2025 | 150 | 0.220 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2024 | 21 | 0.220 |
Why?
|
| Feasibility Studies | 3 | 2023 | 823 | 0.220 |
Why?
|
| Pilot Projects | 3 | 2019 | 1469 | 0.220 |
Why?
|
| Astrocytoma | 1 | 2025 | 112 | 0.220 |
Why?
|
| Anxiety | 3 | 2022 | 1006 | 0.220 |
Why?
|
| Nutrition Surveys | 3 | 2021 | 314 | 0.220 |
Why?
|
| Brain | 6 | 2024 | 3225 | 0.210 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2023 | 154 | 0.210 |
Why?
|
| Olfaction Disorders | 1 | 2024 | 30 | 0.210 |
Why?
|
| Cervical Vertebrae | 1 | 2024 | 121 | 0.210 |
Why?
|
| Wilms Tumor | 1 | 2025 | 119 | 0.210 |
Why?
|
| Follow-Up Studies | 7 | 2025 | 5443 | 0.210 |
Why?
|
| Proton Therapy | 1 | 2025 | 151 | 0.210 |
Why?
|
| Fatigue | 1 | 2024 | 200 | 0.210 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2023 | 42 | 0.200 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2022 | 23 | 0.200 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 39 | 0.200 |
Why?
|
| Infant | 8 | 2025 | 13246 | 0.200 |
Why?
|
| Precision Medicine | 2 | 2024 | 361 | 0.200 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2022 | 75 | 0.200 |
Why?
|
| Medical Oncology | 1 | 2024 | 245 | 0.190 |
Why?
|
| Deafness | 1 | 2023 | 87 | 0.190 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2023 | 82 | 0.190 |
Why?
|
| Patient Outcome Assessment | 1 | 2022 | 94 | 0.190 |
Why?
|
| Sertoli-Leydig Cell Tumor | 1 | 2022 | 18 | 0.190 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 65 | 0.190 |
Why?
|
| Hypertension | 2 | 2022 | 1403 | 0.180 |
Why?
|
| Receptor, trkB | 1 | 2021 | 25 | 0.180 |
Why?
|
| Sensation Disorders | 1 | 2021 | 25 | 0.180 |
Why?
|
| Odds Ratio | 3 | 2020 | 1254 | 0.180 |
Why?
|
| White Matter | 2 | 2020 | 212 | 0.180 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2025 | 301 | 0.180 |
Why?
|
| Frailty | 1 | 2023 | 134 | 0.170 |
Why?
|
| Neuropsychological Tests | 2 | 2023 | 992 | 0.170 |
Why?
|
| Cigarette Smoking | 1 | 2022 | 80 | 0.170 |
Why?
|
| Waiting Lists | 1 | 2022 | 241 | 0.170 |
Why?
|
| Cohort Studies | 6 | 2023 | 5199 | 0.170 |
Why?
|
| Propensity Score | 2 | 2019 | 263 | 0.170 |
Why?
|
| Kidney Neoplasms | 1 | 2025 | 460 | 0.170 |
Why?
|
| Gadolinium | 1 | 2021 | 117 | 0.170 |
Why?
|
| Ganglioglioma | 1 | 2020 | 22 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2025 | 3363 | 0.170 |
Why?
|
| Corpus Callosum | 1 | 2020 | 104 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2025 | 3869 | 0.170 |
Why?
|
| Neoplasms | 3 | 2024 | 2992 | 0.160 |
Why?
|
| Self Report | 5 | 2025 | 553 | 0.160 |
Why?
|
| Early Diagnosis | 1 | 2021 | 199 | 0.160 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2020 | 20 | 0.160 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2020 | 17 | 0.160 |
Why?
|
| Supratentorial Neoplasms | 1 | 2020 | 40 | 0.160 |
Why?
|
| Mental Health | 3 | 2023 | 378 | 0.160 |
Why?
|
| Frail Elderly | 2 | 2023 | 108 | 0.160 |
Why?
|
| Adolescent | 9 | 2025 | 20574 | 0.160 |
Why?
|
| DNA Polymerase II | 1 | 2019 | 21 | 0.160 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 29 | 0.160 |
Why?
|
| Interdisciplinary Research | 1 | 2019 | 10 | 0.160 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2019 | 27 | 0.160 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 154 | 0.160 |
Why?
|
| Genetic Counseling | 1 | 2021 | 246 | 0.150 |
Why?
|
| Sex Factors | 3 | 2021 | 1353 | 0.150 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 1849 | 0.150 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 431 | 0.150 |
Why?
|
| Radiation Dosage | 1 | 2019 | 147 | 0.150 |
Why?
|
| Communication Barriers | 1 | 2018 | 42 | 0.150 |
Why?
|
| Patient Participation | 1 | 2021 | 239 | 0.140 |
Why?
|
| Alzheimer Disease | 2 | 2023 | 882 | 0.140 |
Why?
|
| Interprofessional Relations | 1 | 2019 | 156 | 0.140 |
Why?
|
| Hearing Loss, Unilateral | 1 | 2017 | 8 | 0.140 |
Why?
|
| DNA Mutational Analysis | 2 | 2019 | 841 | 0.140 |
Why?
|
| Minority Health | 1 | 2017 | 13 | 0.140 |
Why?
|
| Aurora Kinase A | 1 | 2018 | 37 | 0.140 |
Why?
|
| Azepines | 1 | 2018 | 65 | 0.140 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2017 | 19 | 0.140 |
Why?
|
| Oximes | 1 | 2017 | 56 | 0.140 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 468 | 0.140 |
Why?
|
| Panniculitis | 1 | 2017 | 19 | 0.130 |
Why?
|
| Neuroimaging | 1 | 2020 | 376 | 0.130 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 899 | 0.130 |
Why?
|
| Hormone Replacement Therapy | 1 | 2020 | 211 | 0.130 |
Why?
|
| Automobile Driving | 1 | 2017 | 34 | 0.130 |
Why?
|
| Biomarkers, Tumor | 4 | 2023 | 1693 | 0.130 |
Why?
|
| Colorectal Neoplasms | 2 | 2022 | 639 | 0.130 |
Why?
|
| Databases, Factual | 2 | 2019 | 1240 | 0.130 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 126 | 0.130 |
Why?
|
| Benzimidazoles | 1 | 2017 | 136 | 0.130 |
Why?
|
| Health Status | 2 | 2017 | 414 | 0.130 |
Why?
|
| Prediabetic State | 1 | 2017 | 63 | 0.130 |
Why?
|
| Adult | 8 | 2025 | 31686 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1156 | 0.130 |
Why?
|
| Young Adult | 5 | 2024 | 9923 | 0.130 |
Why?
|
| Happiness | 1 | 2016 | 13 | 0.120 |
Why?
|
| Biomedical Research | 2 | 2019 | 551 | 0.120 |
Why?
|
| Imidazoles | 1 | 2017 | 218 | 0.120 |
Why?
|
| Germinoma | 1 | 2016 | 32 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2016 | 65 | 0.120 |
Why?
|
| Indoles | 1 | 2017 | 202 | 0.120 |
Why?
|
| Arousal | 1 | 2016 | 82 | 0.120 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 222 | 0.120 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 211 | 0.120 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 399 | 0.120 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 489 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2017 | 289 | 0.120 |
Why?
|
| Cyclin B | 1 | 2014 | 23 | 0.110 |
Why?
|
| Mass Screening | 1 | 2021 | 837 | 0.110 |
Why?
|
| Oncogene Fusion | 1 | 2014 | 26 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2019 | 3418 | 0.110 |
Why?
|
| Medulloblastoma | 1 | 2019 | 571 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 1313 | 0.110 |
Why?
|
| Task Performance and Analysis | 1 | 2014 | 91 | 0.110 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 157 | 0.110 |
Why?
|
| Apolipoprotein E4 | 1 | 2014 | 48 | 0.110 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 148 | 0.110 |
Why?
|
| Retrospective Studies | 6 | 2025 | 17567 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 1915 | 0.110 |
Why?
|
| Glioblastoma | 1 | 2018 | 372 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1340 | 0.110 |
Why?
|
| Prognosis | 3 | 2025 | 5044 | 0.110 |
Why?
|
| Genetic Markers | 1 | 2015 | 624 | 0.100 |
Why?
|
| Environment | 1 | 2014 | 154 | 0.100 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 965 | 0.100 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 448 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 612 | 0.100 |
Why?
|
| Emotions | 1 | 2016 | 366 | 0.100 |
Why?
|
| Postural Balance | 1 | 2014 | 132 | 0.100 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2014 | 128 | 0.100 |
Why?
|
| Genomics | 2 | 2024 | 1677 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 855 | 0.100 |
Why?
|
| Mutation, Missense | 1 | 2017 | 946 | 0.100 |
Why?
|
| Mutation | 4 | 2023 | 6343 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 484 | 0.100 |
Why?
|
| Blood Glucose | 1 | 2017 | 1185 | 0.100 |
Why?
|
| Speech | 2 | 2023 | 78 | 0.100 |
Why?
|
| Hearing Tests | 2 | 2023 | 16 | 0.090 |
Why?
|
| Sarcoma | 1 | 2014 | 209 | 0.090 |
Why?
|
| Incidence | 5 | 2019 | 3396 | 0.090 |
Why?
|
| Disease Management | 1 | 2016 | 565 | 0.090 |
Why?
|
| Diet | 1 | 2019 | 1170 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2016 | 1236 | 0.090 |
Why?
|
| DNA Mismatch Repair | 2 | 2022 | 53 | 0.090 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2023 | 80 | 0.090 |
Why?
|
| Germ Cells | 2 | 2024 | 203 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 624 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 3988 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2014 | 872 | 0.080 |
Why?
|
| Software | 1 | 2014 | 732 | 0.080 |
Why?
|
| Time Factors | 2 | 2019 | 6545 | 0.080 |
Why?
|
| Alleles | 1 | 2014 | 1697 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 1473 | 0.070 |
Why?
|
| Infant, Newborn | 1 | 2021 | 8634 | 0.070 |
Why?
|
| Obesity | 1 | 2019 | 2440 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 1420 | 0.060 |
Why?
|
| Hospitalization | 1 | 2015 | 1922 | 0.060 |
Why?
|
| Audiometry | 2 | 2017 | 23 | 0.060 |
Why?
|
| Blood Pressure | 2 | 2022 | 1411 | 0.060 |
Why?
|
| Tennessee | 2 | 2014 | 34 | 0.060 |
Why?
|
| Heart Failure | 1 | 2018 | 2428 | 0.050 |
Why?
|
| Hand Strength | 1 | 2024 | 60 | 0.050 |
Why?
|
| Social Networking | 1 | 2024 | 18 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 1731 | 0.050 |
Why?
|
| Smell | 1 | 2024 | 131 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2022 | 39 | 0.050 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2022 | 52 | 0.050 |
Why?
|
| Polysomnography | 1 | 2023 | 153 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2022 | 2145 | 0.050 |
Why?
|
| Carotid Arteries | 1 | 2023 | 145 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2023 | 245 | 0.050 |
Why?
|
| Poisson Distribution | 1 | 2021 | 50 | 0.050 |
Why?
|
| Multiple Chronic Conditions | 1 | 2021 | 14 | 0.050 |
Why?
|
| Life Change Events | 1 | 2022 | 65 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2023 | 312 | 0.050 |
Why?
|
| Maryland | 1 | 2021 | 35 | 0.050 |
Why?
|
| Mississippi | 1 | 2021 | 35 | 0.050 |
Why?
|
| North Carolina | 1 | 2021 | 66 | 0.040 |
Why?
|
| Minnesota | 1 | 2021 | 181 | 0.040 |
Why?
|
| Social Class | 1 | 2022 | 207 | 0.040 |
Why?
|
| Bias | 1 | 2021 | 146 | 0.040 |
Why?
|
| Auditory Threshold | 1 | 2019 | 17 | 0.040 |
Why?
|
| Motor Activity | 1 | 2023 | 528 | 0.040 |
Why?
|
| Sleep | 1 | 2023 | 370 | 0.040 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2019 | 23 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2021 | 809 | 0.040 |
Why?
|
| Ethics Committees, Research | 1 | 2019 | 33 | 0.040 |
Why?
|
| China | 1 | 2020 | 292 | 0.040 |
Why?
|
| Exome | 1 | 2024 | 1086 | 0.040 |
Why?
|
| Ophthalmic Artery | 1 | 2019 | 23 | 0.040 |
Why?
|
| Mental Competency | 1 | 2019 | 53 | 0.040 |
Why?
|
| Ethics, Research | 1 | 2019 | 55 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 105 | 0.040 |
Why?
|
| Longitudinal Ligaments | 1 | 2019 | 3 | 0.040 |
Why?
|
| Postmenopause | 1 | 2020 | 155 | 0.040 |
Why?
|
| Carotid Artery, Internal | 1 | 2019 | 65 | 0.040 |
Why?
|
| Research Subjects | 1 | 2019 | 55 | 0.040 |
Why?
|
| Carotid Artery, Common | 1 | 2019 | 69 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 2019 | 99 | 0.040 |
Why?
|
| Biomarkers | 2 | 2019 | 3416 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 410 | 0.040 |
Why?
|
| Delirium | 1 | 2019 | 63 | 0.040 |
Why?
|
| Disease Progression | 1 | 2025 | 2246 | 0.040 |
Why?
|
| Radiation Exposure | 1 | 2019 | 49 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2022 | 910 | 0.040 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2020 | 252 | 0.040 |
Why?
|
| Phenotype | 2 | 2019 | 4577 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2025 | 945 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 964 | 0.030 |
Why?
|
| Contrast Media | 1 | 2021 | 517 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2017 | 52 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2018 | 345 | 0.030 |
Why?
|
| Blood-Brain Barrier | 1 | 2018 | 157 | 0.030 |
Why?
|
| Research Design | 1 | 2021 | 757 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 415 | 0.030 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 736 | 0.030 |
Why?
|
| Internal-External Control | 1 | 2016 | 75 | 0.030 |
Why?
|
| Texas | 1 | 2024 | 3667 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2018 | 815 | 0.030 |
Why?
|
| Focus Groups | 1 | 2016 | 214 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 201 | 0.030 |
Why?
|
| Self Concept | 1 | 2016 | 164 | 0.030 |
Why?
|
| Cerebellar Neoplasms | 1 | 2019 | 461 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2018 | 430 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2015 | 280 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 1013 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 614 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2019 | 999 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2014 | 60 | 0.030 |
Why?
|
| Minority Groups | 1 | 2016 | 251 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1622 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 782 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 407 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 351 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2016 | 455 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 562 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 745 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2016 | 658 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2019 | 1101 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2024 | 3171 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 1584 | 0.020 |
Why?
|
| Patient Selection | 1 | 2016 | 734 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 1864 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2021 | 3719 | 0.020 |
Why?
|
| Apoptosis | 1 | 2018 | 1928 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 2288 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 3794 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2014 | 578 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 1830 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2024 | 13103 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 4760 | 0.020 |
Why?
|
| Animals | 2 | 2018 | 36223 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 2092 | 0.010 |
Why?
|